Multiple endocrine neoplasia type 2 historical perspective: Difference between revisions
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
==Historical Perspective== | ==Historical Perspective==<br> | ||
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center | |||
|+'''''MEN II Historical Background''''' | |||
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Years}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Scientist}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Contribution}} | |||
|- | |||
! style="background: #DCDCDC;" |1954 | |||
! style="background: #F5F5F5;" |Wermer | |||
! style="background: #F5F5F5;" |Reported that [[syndrome]] was transmitted as a dominant trait | |||
|- | |||
! style="background: #DCDCDC;" |1959 | |||
! style="background: #F5F5F5;" |Hazard | |||
! style="background: #F5F5F5;" |Described medullary (solid) [[thyroid carcinoma]] | |||
|- | |||
! style="background: #DCDCDC;" |1961 | |||
! style="background: #F5F5F5;" |Sipple | |||
! style="background: #F5F5F5;" |Described a combination of a [[pheochromocytoma]], [[medullary thyroid carcinoma]] and [[parathyroid adenoma]] | |||
|- | |||
! style="background: #DCDCDC;" |1965 | |||
! style="background: #F5F5F5;" |Schimke and Hartmann | |||
! style="background: #F5F5F5;" |Described a syndrome of pheochromocytoma and medullary thyroid carcinoma with abundant amyloid stroma<ref name="pmid5844561">{{cite journal| author=Schimke RN, Hartmann WH| title=Familial amyloid-producing medullary thyroid carcinoma and pheochromocytoma. A distinct genetic entity. | journal=Ann Intern Med | year= 1965 | volume= 63 | issue= 6 | pages= 1027-39 | pmid=5844561 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5844561 }} </ref> | |||
|- | |||
! style="background: #DCDCDC;" |1966 | |||
! style="background: #F5F5F5;" |Williams | |||
! style="background: #F5F5F5;" |Described the combination of mucosal neuromas, [[pheochromocytoma]] and [[medullary thyroid carcinoma]] | |||
|- | |||
! style="background: #DCDCDC;" |1968 | |||
! style="background: #F5F5F5;" |Steiner | |||
! style="background: #F5F5F5;" |Introduced the term "multiple endocrine neoplasia" (MEN) to describe disorders featuring combinations of [[endocrine]] [[tumor]]s and proposed the terms '[[Wermer syndrome]]' for MEN 1 and '[[Sipple syndrome]]' for MEN 2 | |||
|- | |||
! style="background: #DCDCDC;" |1974 | |||
! style="background: #F5F5F5;" |Sizemore | |||
! style="background: #F5F5F5;" |Showed that the MEN 2 category included two groups of patients with MTC and [[pheochromocytoma]]: one with [[parathyroid]] [[disease]] and a normal appearance (MEN 2A) and the other without [[parathyroid]] [[disease]] but with mucosal neuromas and mesodermal abnormalities ([[MEN 2B]]) | |||
|- | |||
! style="background: #DCDCDC;" |1993 | |||
! style="background: #F5F5F5;" | | |||
! style="background: #F5F5F5;" |RET germline mutations were recognized as the causative molecular alterations in MEN 2 syndromes | |||
|- | |||
! style="background: #DCDCDC;" |1998 | |||
! style="background: #F5F5F5;" | | |||
! style="background: #F5F5F5;" |MEN1 gene was cloned<ref name="Guru1998">Guru SC, Manickam P, Crabtree JS, Olufemi SE, Agarwal SK, Debelenko LV. Identification and characterization of the [[multiple endocrine neoplasia type 1]] (MEN1) gene. ''J Intern Med'' 243(6) 433-9</ref> | |||
|} | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} |
Revision as of 13:52, 21 September 2015
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 historical perspective On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 historical perspective |
FDA on Multiple endocrine neoplasia type 2 historical perspective |
CDC on Multiple endocrine neoplasia type 2 historical perspective |
Multiple endocrine neoplasia type 2 historical perspective in the news |
Blogs on Multiple endocrine neoplasia type 2 historical perspective |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
==Historical Perspective==
Years | Scientist | Contribution |
---|---|---|
1954 | Wermer | Reported that syndrome was transmitted as a dominant trait |
1959 | Hazard | Described medullary (solid) thyroid carcinoma |
1961 | Sipple | Described a combination of a pheochromocytoma, medullary thyroid carcinoma and parathyroid adenoma |
1965 | Schimke and Hartmann | Described a syndrome of pheochromocytoma and medullary thyroid carcinoma with abundant amyloid stroma[1] |
1966 | Williams | Described the combination of mucosal neuromas, pheochromocytoma and medullary thyroid carcinoma |
1968 | Steiner | Introduced the term "multiple endocrine neoplasia" (MEN) to describe disorders featuring combinations of endocrine tumors and proposed the terms 'Wermer syndrome' for MEN 1 and 'Sipple syndrome' for MEN 2 |
1974 | Sizemore | Showed that the MEN 2 category included two groups of patients with MTC and pheochromocytoma: one with parathyroid disease and a normal appearance (MEN 2A) and the other without parathyroid disease but with mucosal neuromas and mesodermal abnormalities (MEN 2B) |
1993 | RET germline mutations were recognized as the causative molecular alterations in MEN 2 syndromes | |
1998 | MEN1 gene was cloned[2] |
References
- ↑ Schimke RN, Hartmann WH (1965). "Familial amyloid-producing medullary thyroid carcinoma and pheochromocytoma. A distinct genetic entity". Ann Intern Med. 63 (6): 1027–39. PMID 5844561.
- ↑ Guru SC, Manickam P, Crabtree JS, Olufemi SE, Agarwal SK, Debelenko LV. Identification and characterization of the multiple endocrine neoplasia type 1 (MEN1) gene. J Intern Med 243(6) 433-9